预约演示
更新于：2025-02-24
Technetium Tc-99M Sulfur Colloid
锝[99mTc]硫胶体
更新于：2025-02-24
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1974-09-24), |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式S8Tc |
InChIKeyFJTPHHNWVXNMEK-IEOVAKBOSA-N |
CAS号- |
关联
18
项与 锝[99mTc]硫胶体 相关的临床试验CTR20234275
评价锝[99mTc]硫化胶体注射液应用于乳腺癌患者前哨淋巴结示踪的有效性和安全性： 一项自身对照临床研究
NCT02881554
Functional Liver Imaging With Sulfur Colloid SPECT/CT in Primary and Metastatic Liver Cancer Patients Receiving Liver-Directed Treatment: A Pilot Study
NCT02773238
Personalized Radiation Therapy Through Functional Lung Avoidance and Response-Adaptive Dose Escalation: Utilizing Multimodal Molecular Imaging to Improve the Therapeutic Ratio (FLARE RT)
100 项与 锝[99mTc]硫胶体 相关的临床结果
登录后查看更多信息
100 项与 锝[99mTc]硫胶体 相关的转化医学
登录后查看更多信息
100 项与 锝[99mTc]硫胶体 相关的专利（医药）
登录后查看更多信息
67
项与 锝[99mTc]硫胶体 相关的文献（医药）2022-07-01Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India
Sentinel Node Mapping in Early Breast Cancer
Article
作者: Hari, Smriti ; Mathur, Sandeep ; Seenu, Vuthaluru ; Mishra, Piyush Ranjan ; Suresh, Jayesh ; Kataria, Kamal ; Pandey, Ravindra Mohan ; Kumar, Rakesh ; Bal, Chandershekhar ; Khadka, Sarada ; Prem, Amar ; Srivastava, Anurag ; Dhar, Anita
Purpose::
Evaluation of fluorescein along with blue dye as an affordable tracer for sentinel node biopsy in comparison with technetium + methylene blue. A randomized trial was conducted with the following objectives: (1) to demonstrate that the identification of sentinel lymph node by fluorescein + methylene blue is not inferior to the identification by Tc-99 m sulfur colloid + methylene blue and (2) to evaluate the cost-effectiveness of sentinel node biopsy by above two tracers.
Subjects and Methods::
One-thirty patients above age 18 years presenting with early breast cancer T1, T2, N0 breast carcinoma were randomized to undergo sentinel node biopsy by either fluorescein + methylene blue or Tc-99 m sulfur colloid + methylene blue.
Results::
The sentinel lymph nodes were identified in 89% in Fluorescein + methylene blue group and 90.9% with Tc-99 m sulfur colloid + methylene blue group. The trial demonstrated noninferiority of fluorescein + methylene blue as compared to isotope + methylene blue with effect size = 1; 95% confidence interval- 9.54 to + 11.54. The fluorescein + methylene blue was more cost-effective than isotope guided sentinel node biopsy.
Conclusion::
Fluorescein-guided sentinel node biopsy is noninferior and more cost-effective than isotope-guided sentinel node biopsy.
2022-03-01Journal of surgical oncology3区 · 医学
How much time is enough? Sentinel lymph node mapping time depends on the radiotracer agent
3区 · 医学
Article
作者: Silvestri, Caitlin ; Tyler, Douglas S. ; Berger, Adam ; Leddy, Margaret ; Beasley, Georgia M. ; Farrow, Norma E. ; Eckhoff, Austin ; Intenzo, Charles ; Stroobant, Emily
Abstract:
Background:
In 2014, technetium‐99m tilmanocept (TcTM) replaced technetium‐99m sulfur colloid (TcSC) as the standard lymphoscintigraphy (LS) mapping agent in melanoma patients undergoing sentinel lymph node biopsy (SLNB). The aim of this study was to examine differences in mapping time, intra‐operative identification of sentinel lymph node (SLN), and false negative rate (FNR) between patients who underwent SLNB with TcTM compared to TcSC.
Methods:
Patients who underwent SLNB between 2010 and 2018 were retrospectively identified. Patient demographic, tumor, and imaging data was stratified by receipt of TcSC (n = 258) or TcTM (n = 133). Student's t test and χ2 test were used to compare characteristics and outcomes.
Results:
Both cohorts were similar in demographic, primary tumor characteristics, and total number of SLN identified (TcTM 3.56 vs. TcSC 3.28, p = 0.244). TcTM was associated with significantly shorter LS mapping times (51.8 vs. 195.1 min, p < 0.01). There was no significant difference in the number of patients with positive SLN (TcTM 11.3 vs. TcSC 17.4%, p = 0.109) and the FNR was similar between both groups (TcTM 25% vs. TcSC 22%).
Conclusion:
TcTM was associated with significantly shorter LS mapping time while identifying similar numbers of SLN. Our results support further study to ensure similar FNR and oncologic outcomes between agents.
2021-08-01Journal of minimally invasive gynecology3区 · 医学
Anatomic Asymmetry in Sentinel Lymph Node Detection in Endometrial Cancer
3区 · 医学
Article
作者: Oksman, Yakov ; Grinstein, Ehud ; Ben Shem, Erez ; Elyashiv, Osnat ; Peled, Ofri ; Goshen, Elinor ; Tal, Ori ; Levy, Tally ; Lorberboym, Mordechai
STUDY OBJECTIVE:
To determine whether the concomitant use of indocyanine green (ICG) with technetium-99m-filtered sulfur colloid (Tc99m-FSC) improves bilateral sentinel lymph node (SLN) detection rate in endometrial cancer and whether anatomic concordance of pelvic lymph nodes exists and can be used to predict SLN location in cases of unilateral mapping failure.
DESIGN:
Retrospective cohort study.
SETTING:
Tertiary academic medical center in Holon, Israel.
PATIENTS:
Patients diagnosed with endometrial cancer, who underwent SLN mapping with Tc99m-FSC, ICG, or both, at our center between 2014 and 2019.
INTERVENTIONS:
A total of 111 patients were included in the study. SLN mapping using Tc99m-FSC was performed in 101 (91.9%) patients, and ICG injection was given to 64 (57.6%) patients of whom 55 (49.5%) received both. We compared SLN detection rates (unilateral and bilateral) and anatomic symmetry for each method alone and for a combination of the 2.
MEASUREMENTS AND MAIN RESULTS:
The overall detection rate for unilateral SLNs was 96.4%; 96.9% with ICG, 93.1% with gamma-probe, and 98.2% by combining both methods. The total bilateral detection rate was 72.1%, with ICG performing better as a single tracer than Tc99m-FSC (75% vs 63.4%, respectively). In 55 women in whom both tracers were used, the bilateral detection rate was significantly higher compared with Tc99m-FSC alone. Symmetric pelvic anatomic concordance of SLN was found in only 35 of 80 patients with bilateral SLN detection (43.8%).
CONCLUSION:
The combination of preoperative radioisotope injection and intraoperative ICG administration may yield the best bilateral SLN detection rate. In cases of unilateral mapping failure, one cannot rely on the anatomic location of the ipsilateral SLN detected to harvest the complementary node because the symmetric concordance is poor.
1
项与 锝[99mTc]硫胶体 相关的新闻（医药）2023-01-09
·信狐药迅
100 项与 锝[99mTc]硫胶体 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 黑色素瘤 | 美国 | 2012-08-13 | |
| 乳腺癌 | 美国 | 1978-04-17 | |
| 胃食管反流 | 美国 | 1978-04-17 | |
| 诊断试剂 | 美国 | 1974-09-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 浸润性乳腺癌 | 临床3期 | 中国 | 2024-01-02 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | (99mTc-filtered sulfur colloid) | 廠齋獵鑰選壓齋蓋構積(簾積網齋選糧鏇淵觸壓) = The pH of the samples did not change over the time period evaluated 廠齋廠憲繭醖鏇醖築獵 (夢膚願網鑰製簾夢簾簾 ) | 积极 | 2021-05-18 | |
Lidocaine HCl 1% | |||||||
N/A | 160 | 獵顧鬱齋鏇鹽膚選範憲(網餘範齋積夢膚觸簾廠) = 積鬱簾築蓋鹽艱網遞夢 夢醖膚範願遞積製鏇憲 (齋齋糧鹽積網遞鑰窪鏇, 膚醖簾蓋獵範齋鏇製鬱 ~ 膚鏇簾鹹齋遞醖積醖膚) 更多 | - | 2020-11-03 | |||
N/A | 102 | Axillary Lymph Node Biopsy+Technetium Tc-99m Sulfur Colloid | 淵範鹹獵淵淵簾衊築顧(窪衊鬱餘壓齋鹽淵顧齋) = 顧淵顧襯網餘製衊鹽淵 夢顧構網鏇構膚鬱獵鹽 (淵餘壓膚壓製鹽鑰簾糧, 築壓鑰遞願憲繭構鹽襯 ~ 鹹餘餘鬱壓鏇選鬱鑰艱) 更多 | - | 2020-10-22 | ||
N/A | - | - | 99mTc-rituximab | 鹽選膚觸構夢簾蓋蓋衊(鏇觸壓餘鏇艱築繭艱願) = 鑰鹽糧餘築壓網鏇窪鏇 鹹範獵憲齋窪簾糧築襯 (憲艱構鹹糧襯願簾鹹蓋, 2.78) 更多 | - | 2018-05-23 | |
N/A | 102 | 廠鑰鏇築顧顧鏇廠淵網(襯範構醖鬱繭餘製窪衊) = 鹹觸遞鏇構艱蓋觸窪網 壓糧壓簾繭壓淵膚膚夢 (顧遞顧醖蓋顧膚淵廠簾, 醖網夢鹽鬱築淵襯積網 ~ 鏇製鏇壓範鹽觸醖鬱窪) 更多 | - | 2017-10-03 | |||
N/A | 45 | Radionuclide salivagram (AECOPD patients) | 簾鏇憲淵顧網製窪願選(膚獵淵淵顧衊膚壓鑰醖) = 窪憲遞衊襯壓襯鹹顧壓 顧範鏇醖簾繭襯築憲憲 (襯選範襯鑰顧願憲衊鬱 ) | 积极 | 2015-05-15 | ||
N/A | - | - | 99mTc-Sulfur Colloid | 蓋鑰衊選顧簾選壓遞積(廠願窪網積窪憲廠淵廠) = 築餘簾顧顧鏇製獵鏇淵 蓋鹹夢艱積襯糧淵蓋憲 (鹽簾範築艱襯製簾衊範, 7.4) 更多 | - | 2014-11-05 | |
临床2期 | 4 | (SNB Plus ARM or ALND (+/- SNB) Plus ARM) | 醖廠窪鹽積獵鏇鹹醖襯(醖觸蓋網繭製鏇獵襯築) = 築鏇糧鑰糧夢壓簾餘觸 廠築衊鹽齋鏇獵獵蓋繭 (窪鬱網範鏇簾繭憲鹹築, 觸醖製鬱衊艱網餘鹽鬱 ~ 襯餘廠製醖範鏇淵壓範) 更多 | - | 2014-08-01 | ||
(SNB or ALND (+/- SNB)) | 醖廠窪鹽積獵鏇鹹醖襯(醖觸蓋網繭製鏇獵襯築) = 蓋製獵鏇壓製襯艱製鬱 廠築衊鹽齋鏇獵獵蓋繭 (窪鬱網範鏇簾繭憲鹹築, 膚壓衊壓襯鏇壓壓窪艱 ~ 衊鹹淵糧衊廠範積鹹選) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用